Short Interest in Codexis, Inc. (NASDAQ:CDXS) Increases By 20.5%

Codexis, Inc. (NASDAQ:CDXS) was the target of a significant increase in short interest in January. As of January 15th, there was short interest totalling 2,290,000 shares, an increase of 20.5% from the December 31st total of 1,900,000 shares. Based on an average daily trading volume, of 668,900 shares, the days-to-cover ratio is presently 3.4 days.

Institutional Trading of Codexis

Institutional investors have recently added to or reduced their stakes in the business. Rhumbline Advisers boosted its holdings in shares of Codexis by 10.5% in the 4th quarter. Rhumbline Advisers now owns 115,080 shares of the biotechnology company’s stock valued at $549,000 after buying an additional 10,902 shares during the period. White Pine Capital LLC boosted its stake in Codexis by 28.1% in the fourth quarter. White Pine Capital LLC now owns 193,936 shares of the biotechnology company’s stock valued at $925,000 after acquiring an additional 42,512 shares during the period. China Universal Asset Management Co. Ltd. acquired a new position in Codexis in the fourth quarter valued at approximately $82,000. Kingswood Wealth Advisors LLC bought a new position in shares of Codexis during the fourth quarter valued at approximately $79,000. Finally, Inspire Investing LLC bought a new stake in shares of Codexis in the 4th quarter worth approximately $405,000. Institutional investors own 78.54% of the company’s stock.

Codexis Stock Down 6.9 %

CDXS stock traded down $0.31 during mid-day trading on Friday, hitting $4.19. 663,429 shares of the company were exchanged, compared to its average volume of 643,871. The company has a current ratio of 3.21, a quick ratio of 3.15 and a debt-to-equity ratio of 0.39. Codexis has a twelve month low of $2.53 and a twelve month high of $6.08. The firm has a fifty day simple moving average of $4.92 and a 200 day simple moving average of $3.85. The company has a market capitalization of $340.98 million, a PE ratio of -4.82 and a beta of 2.13.

Codexis (NASDAQ:CDXS) last issued its earnings results on Thursday, October 31st. The biotechnology company reported ($0.29) EPS for the quarter, missing the consensus estimate of ($0.25) by ($0.04). Codexis had a negative return on equity of 71.56% and a negative net margin of 96.35%. The firm had revenue of $12.83 million during the quarter, compared to analyst estimates of $11.64 million. During the same quarter in the previous year, the business posted ($0.26) EPS. On average, research analysts forecast that Codexis will post -0.77 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Benchmark reiterated a “hold” rating on shares of Codexis in a research note on Monday, November 4th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $11.00 price target on shares of Codexis in a research note on Friday, November 22nd.

About Codexis

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.